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PUBLIC USE OR EXPERIMENTAL USE: ARE
CLINICAL TRIALS SUSCEPTIBLE TO ANOTHER
ATTACK SIMILAR TO THAT IN SMITHKLINE
BEECHAM CORP. V.APOTEX CORP.?
NIMALKA WICKRAMASEKERA*

"The Holy Grail of chemical composition of matter claims is often
something like: 'Crystalline paroxetine hydrochloride hemihydrate.'"
INTRODUCTION

In what may appear, at first glance, to be a ground breaking decision,
the United States Court of Appeals for the Federal Circuie ("the Federal

* J.D. Candidate, May 2006, The John Marshall Law School. For their constant
support, the author would like to thank her parents, Ursula and Hemasiri Wickramasekera,
her brothers, Duminda and Ananda Wickramasekera, her sister-in-law, Ramani Damera,
and her nephew and niece, Sohan and Sonali Wickramasekera. The author would also like
to thank the members and board of The John Marshall Law Review for their editorial
assistance, especially Manish Mehta. Last, but not least, the author would like to give a
special thanks to her husband, Adam Storer, for his limitless patience and constant
support.
1. Ivor R. Elrifi & Nicholas P. Triano, III, The Paxil Case: Composition of Matter
Claims, Polymorphs and 'Follow-on' Patents, 9 INTELL. PROP. STRATEGIST 3 (2003)
(reciting independent Claim 1 of U.S. Patent No. 4,721,723 (filed Oct. 23, 1986) (issued
January 26, 1988), the active ingredient in GlaxoSmithKline's blockbuster anti-depressant
drug Paxil®).
2. The federal district courts have original and exclusive jurisdiction over civil
actions arising under any act of Congress relating to patents. 28 U.S.C. § 1338 (2000). In
1982, Congress created the United States Court of Appeals for the Federal Circuit pursuant
to the Federal Courts Improvement Act of 1982. 32 AM. JUR. 2D Federal Courts § 603
(2004). The Court of Appeals for the Federal Circuit has exclusive appellate jurisdiction
over all federal district court cases relating to patents, regardless of the circuits in which
the district courts are located. 28 U.S.C. § 1295 (2000). The Court of Appeals for the
Federal Circuit was a consolidation of its two predecessor courts, the United States Court
of Claims and the United States Court of Customs and Appeals. 32 AM. JUR. 2D Federal
Courts § 603. The Court of Claims and the Court of Customs and Appeals were merged
into a single Court of Appeals. Daniel J. Meador, United States Court of Appeals for the
Federal Circuit Tenth Anniversary Commemorative Issue: Article: Origin of the Federal
Circuit: A PersonalAccount, 41 AM. U.L. REV. 581, 620 (1992). This, in effect, allowed
the Federal Circuit to promote "procedural efficiency, judicial structure, and heightened
coherence in [patent] law." Id. The Court of Appeals for the Federal Circuit adopted as
binding precedent the holdings of its predecessor courts. South Corp. v. United States,
690 F.2d 1368, 1369-71 (Fed. Cir. 1982). The Federal Circuit has nationwide jurisdiction
over appeals involving patents and is headquartered in Washington, D.C., but may hold
sessions where any Court of Appeals may sit. 32 AM. JUR. 2D FederalCourts § 603.
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Circuit") held in SmithKline Beecham Corp. v. Apotex Corp.3 that a patent
claim to paroxetine hydrochloride hemihydrate,4 the active ingredient of
GlaxoSmithKline's antidepressant drug Paxil®,5 was invalid under the 35
U.S.C. § 102(b) public use bar. The Federal Circuit initially found the
patent claim invalid because the clinical trials conducted to test the drug
constituted public use within the meaning of the statute.7 This decision
sparked concern in the intellectual property community, 8 and produced
headlines such as, "Tests to Establish Safety of Drug Bar Patentability." 9
One commentator expressed concern over the adverse effects of the
decision on brand name pharmaceutical manufacturers and their ability to
develop new drugs.' 0 She urged the legislature and the courts to handle the
3. SmithKline Beecham Corp. v. Apotex Corp., 365 F.3d 1306, 1317-18 (Fed. Cir.
2004), vacated as to issue of experimental use by 403 F.3d 1328 (Fed. Cir. 2005),
superseded by 403 F.3d 1331 (Fed. Cir. 2005) (invalidating patent claim as inherently
anticipated under 35 U.S.C. § 102(b)).
4. The claim at issue, independent claim 1 of the '723 patent, entitled AntiDepressant Crystalline Paroxetine Hydrochloride Hemihydrate, recites, in its entirety,
"Crystalline paroxetine hydrocholoride hemihydrate." Id.
5. Paxil.com, An Introduction to Paxil®, http://www.paxil.com/aboutnwint.html
(last visited Nov. 1, 2004).
6. 35 U.S.C. § 102 (2000) ("A person shall be entitled to a patent unless ... (b) the
invention was patented or described in a printed publication in this or a foreign country or
in public use or on sale in this country, more than one year prior to the date of the
application for patent in the United States.... ").
7. SmithKline Beecham Corp., 365 F.3d at 1318. The court first defined the invention
in Claim I as the bare paroxetine hydrochloride heinihydrate compound because the patent
recited only the compound name without any further language regarding its efficacy,
commercial value, or pharmaceutical value. Id. The court then held that the clinical trials
designed to test the safety and efficacy of the compound as an antidepressant for FDA
approval cannot constitute experimental use because the pharmaceutical benefits of the
drug as an antidepressant were not features of the claimed invention. Id. See discussion
infra Part IV § 1 (stating that experimental use must pertain to the invention claimed).
8. Susan K. Knoll & Michelle Replogle, PriorArt Under 35 U.S.C. Section 102 (a)
and (b), 793 PLI/PAT 9, 13 (2004). "[A] patent claim to a drug compound was invalid
under the § 102(b) public use bar when the patentee conducted clinical trials on the safety
and efficacy of the drug more than one year before to [sic] the filing o[f] the patent." Id.
Furthermore, "[i]n the present case, the critical date for the 102(b) bar is Oct. 23, 1985,
leaving the question of whether the clinical trials beginning in May 1985 qualify as
experimental use." Appellate Panel Issues Ruling On Experimental Use Negation, Claim
Clock, 12-15 MEALEY'S LITIG. REP. INTELL. PROP. 11 (2004).
9. Kathlyn Card-Beckles, Tests to Establish Safety of Drug Bar Patentability, 10
INTELL. PROP. STRATEGIST 7 (2004).
10. Teresa 0. Bittenbender & John W. Ryan, Recent Developments in Pharmaceutical
Patent Litigation, 16 J. PROPRIETARY RTS. 5, 7 (2004).
In SmithKline Beecham Corp. v. Apotex Corp., the Federal Circuit held that a
patent claiming the active ingredient of the antidepressant Paxil was infringed by
the generic drug maker Apotex by very small amounts of the claimed compound
but that clinical trials required for FDA approval conducted prior to filing the patent
application barred SmithKline from patent protection. Because the patent claim was
directed to the compound itself as opposed to its commercial embodiments, the
clinical trials on patients could not be considered experimental use. When a claim is
directed to a compound and does not recite use of the compound, the experimental
use doctrine terminates when the compound is synthesized. Put another way, in
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intellectual property rights of the pharmaceutical industry with the same
regard afforded to other technologies, and called for a halt to holding the
pharmaceutical industry to a "much higher standard" in patent protection.l"
To obtain a United States patent, an inventor must file a patent
application 12 within one year after placing the invention in public use in the
14
United States. 3 This requirement, commonly known as the public use bar,
serves several public interests: It encourages the inventor to assert his or her
rights promptly to protect the public from being deprived of new
inventions; 5 prevents the inventor from extending his or her monopoly
beyond the statutorily prescribed period; 6 and discourages the inventor from
removing inventions from the public domain.17
To balance the scales between the rights of the public, which include
the rights of inventors,' 8 American jurisprudence created the experimental
order to fall within the experimental use doctrine, the experimentation must be on a
claimed element. This decision conflicts with numerous decisions of the Federal
Circuit and limits the ability to experiment with a chemical compound before filing
a patent application. This holding is likely to give pause to name brand
manufacturers on how or where to conduct clinical trials on newly developed drugs,
while still maintain protection of their intellectual property.
Id.
11. Id.
12. The critical date with respect to patent law is the date on which the patent
application was filed. See generally 60 AM. JUR. 2D Patents §§ 262, 263 (2004)
(explaining the importance of when the patent was filed in determining the validity of the
patent). From this date forward, no use can be held against the inventor as constituting
public use within the meaning of 35 U.S.C. § 102(b) (2000).
13. 35 U.S.C. § 102.

14. 35 U.S.C. § 102(b) embodies both the public use and the on sale bars to
patentability. See generally Timothy R. Holbrook, The More Things Change, The More
They Stay The Same. Implications of Pfaff v. Wells Electronics, Inc. and the Quest for
Predictabilityin the On-Sale Bar, 15 BERKELEY TECH. L.J. 933 (2000) (offering helpful
background regarding the on-sale bar).
15. Kurtis A. Kemper, Annotation, When is Public Use of Invention, More Than One
Year Before Patent Application, for Experimental Purposes,so That 35 U.S. CA § 102(b)
Does Not Prevent Issuance of Valid Patent, 171 A.L.R. FED. 39 (2004). See also RCA
Corp. v. Data Gen. Corp., 887 F.2d 1056, 1062 (Fed. Cir. 1989) (proposing that one policy
behind the public bar is to disclose new inventions to the public).
16. Kemper, supra note 15; RCA Corp., 887 F.2d at 1062.
17. Manville Sales Corp. v. Paramount Sys., Inc., 917 F.2d 544, 550 (Fed. Cir. 1990)
(citation omitted); Allied Colloids Inc. v. Am. Cyanamid Co., 64 F.3d 1570, 1574 (Fed.
Cir. 1995); Kemper, supra note 15, at 39.
18. TP Labs., Inc. v. Prof'l Positioners, Inc., 724 F.2d 965, 968 (Fed. Cir. 1984).
The general purpose behind all the [§ 102(b)] bars is to require inventors to assert
with due diligence their right to a patent through the prompt filing ...of a patent
application....
In contrast to these considerations, the public interest is also
deemed to be served by allowing an inventor time to perfect his invention, by
public testing, if desired, and prepare a patent application.
Id. (citations omitted). See generally Tone Bros., Inc., v. Sysco Corp., 28 F.3d 1192, 1198
(Fed. Cir. 1994) (listing underlying policies that define the public use bar as (1)
discouraging removal of inventions the public reasonably believes are in the public
domain; (2) encouraging prompt disclosure of inventions by the inventor; (3) allowing the
inventor a reasonable amount of time to determine whether a patent has economic value;
and (4) prohibiting the inventor from extending the monopoly conferred by the statute
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use doctrine.' 9 This doctrine promotes the public interest by providing the
inventor an opportunity to perfect the invention.20 Use by the inventor 2' that
falls under the rubric of experimental use is not public use 22 within the
meaning of § 102(b),23 and therefore, does not start the clock on the public
use bar.24

The main issue raised by the Federal Circuit decision in SmithKline
Beecham Corp. was whether clinical trials may constitute public use.
Without discussing its reasons, the Federal Circuit, sitting en banc,
subsequently vacated the portion of this decision regarding the issue of
experimental use. 2 6 On remand, the Federal Circuit panel replaced the
vacated decision with a new one invalidating the same patent claim for a
different reason, inherent anticipation. 7 The issue of whether clinical trials
may constitute public use, therefore, remains alive. This Comment will
explore the reasoning behind the prior SmithKline Beecham Corp.28 decision.
As this Comment will discuss, SmithKline Beecham Corp.29 did not stand for
the sweeping proposition that clinical trials designed to test the safety and
through commercial exploitation of the invention); Baxter Int'l, Inc. v. Cobe Labs., Inc.,
88 F.3d 1054, 1058 (Fed. Cir. 1996); Lough v. Brunswick Corp., 86 F.3d 1113, 1119 (Fed.
Cir. 1996).
19. William C. Rooklidge & Stephen C. Jensen, Common Sense, Simplicity and
Experimental Use Negation of the Public Use and On Sale Bars to Patentability,29 J.
MARSHALL L. REV. 1, 8-10 (1995); see also Kemper, supra note 15, at 39 (discussing the
implementation and function of the experimental use doctrine).
20. TPLabs., Inc., 724 F.2d at 968.
21. The experimental use doctrine to which this Comment pertains is use by the
inventor. Another experimental use doctrine pertains to use by an accused infringer.
Shashank Upadhye, To Use or Not to Use: Reforming Patent Infringement, the Public Use
Bar, and the Experimental Use Doctrine as Applied to Clinical Testing of Pharmaceutical
and Medical Device Inventions, 4 MINN. INTELL. PROP. REV. 1, 11 (2002) [hereinafter
Reforming Patent Infringement]. With scientific inventions, an accused infringer will
often be a not-for-profit organization, such as a university, or a generic drug manufacturer.
See generally Shashank Upadhye, UnderstandingPatent Infringement Under 35 U.S.C.
§ 271 (e): The Collisions Between Patent, Medical Device, and Drug Laws, 17 SANTA
CLARA COMPUTER & HIGH TECH. L.J. 1 (2000) [hereinafter Understanding Patent
Infringement]. Accused infringers often raise the defense that their conduct, and not that
of the inventor, constituted experimental use and is thus non-infringing. Id.
22. It is worth mentioning that an accused patent infringer will raise public use by the
inventor as a defense to infringement. Kemper, supra note 15, at 39. Public use is brought
up during litigation to invalidate the patent, and thereby excuse the accused infringer. One
commentator has described the public use bar as the "last refuge of the desperate
infringer." Rooklidge, supra note 19, at 46.
23. 35 U.S.C. § 102. See generally Reforming Patent Infringement, supra note 21
(discussing the distinction between experimental use and public use by the inventor).
24. 35 U.S.C. §102 has a one year time period from when the time the invention was

offered for public use to file a patent application. Reforming Patent Infringement, supra
note 21, at 4.
25. 365 F.3d 1306 (Fed. Cir. 2004).
26. 403 F.3d 1328, 1329 (Fed. Cir. 2005).
27. 403 F.3d 1331, 1345 (Fed. Cir. 2005) (invalidating patent claim as inherently
anticipated under 35 U.S.C. § 102(b)).
28. 365 F.3d 1306 (Fed. Cir. 2004).
29. Id.
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efficacy of an invention will necessarily constitute public use,30 nor was the
case irreconcilable with other Federal Circuit decisions.
Part II of this Comment will provide a background of the public use bar
to patentability and will discuss the emergence of the judicially created
experimental use doctrine. Part III will analyze whether SmithKline
Beecham Corp.3 1 followed current case law. Part IV will allay concerns that
the decision of SmithKline Beecham Corp. undermined certainty and
predictability in patent law by proposing that the decision would have set
forth clearer boundaries for the doctrine of experimental use.
I.

EXPERIMENTAL USE NEGATION OF THE PUBLIC

USE BAR

A. Public Use
1.

The PatentActs

The language of the Patent Act of 1793 prevented the issuance of a
patent for an invention known or used before the application.32 The Patent
Act of 1836 prevented the issuance of a patent for an invention that was in
public use or on sale before the application.33 The Patent Act of 1839
created a two-year period during which the invention could be in public use

30. A word on utility is warranted here. To obtain a patent on a process, machine,
manufacture, or composition of matter, the discovery must not only be new, it must be
useful. 35 U.S.C. § 101. According to 35 U.S.C § 101, "Whoever invents or discovers
any new and useful process, machine, manufacture, or composition of matter, or any new
and useful improvement thereof, may obtain a patent therefore, subject to the conditions
and requirements of this title." Id. This is known as the minimum utility requirement for
inventions and may pose a significant problem for chemical inventions. 1-4 DoNALD S.
CHIsUM, CHISUM ON PA TENTS § 4.02 (2004). With chemical inventions, it can be difficult
to demonstrate sufficient minimum utility. Id. A pharmaceutical drug may be patented by
claiming only its chemical structure. Id. This chemical composition is subject to the same
minimum utility requirements imposed on all other inventions, which would lead some to
argue that clinical trial testing is the only experimental testing sufficient to prove utility.
Id. It must be kept in mind, however, that the utility requirement is one of minimum
utility, and that requirement is sufficiently met when a drug demonstrates that it has any
pharmacological activity. See Reforming Patent Infringement, supra note 21, at 58 (citing
In re Chilowsky, 229 F.2d 457, 461-62 (C.C.P.A. 1956)). The requirement of minimum
utility can thus be met by in vivo testing, short of testing in humans. See Nelson v.
Bowler, 626 F.2d 853, 856 (C.C.P.A. 1980) (The court stated that because "it is crucial to
provide researchers with an incentive to disclose pharmacological activities in as many
compounds as possible, we conclude that adequate proof of any such activity constitutes a
showing of practical utility").
31. 365 F.3d 1306 (Fed. Cir. 2004).
32. Kemper, supra note 15, at 62 (discussing that the Patent Act of 1793 authorized a
grant of a patent for an invention "not known or used before the application"). A strict
reading of the language poses a problem because the inventor necessarily knows of the
invention before the application for a patent. Rooklidge, supra note 19, at 9.
33. Kemper, supra note 15, at 62. A strict reading of the Patent Act of 1836 would
also pose a problem because inventors may need to test an invention in the public domain
before filing a patent application. Rooklidge, supra note 19, at 9.
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or on sale before the application for a valid patent to issue. 34 The Patent Act
of 1939 reduced the grace period to one year.
2.

The Early Cases - Illustrationsof Public Use

One of the first and best-known cases of public use is the case of
Egbert v. Lippmann,36,3the "Corset Case." 37 On July 17, 1866, Samuel H.
Barnes applied 38 for a patent on several corset designs he invented between
January and May 1855.39 At the time of Barnes's application, the Patent Act
of 1839 was in effect, allowing an inventor a two-year period to use the
invention publicly before application.4 ° In 1855 and 1858, Barnes made the
corset steels that embodied his patented invention and presented them to
Egbert,4 ' who wore them for several years.4 2 Barnes also showed his corset
inventions to Joseph H. Sturgis in 1863.43 The Supreme Court was
confronted the issue of whether Barnes's use of the invention for over eleven
years before application constituted public use within the meaning of the
statute. 44
The Supreme Court, in holding that Barnes's invention was in public
use within the meaning of the statute,45 posited three guidelines that would
broadly define "public use" within the meaning of the statute.
First, the use of a single patented article in public is sufficient to
constitute public use within the meaning of the statute.46 Second, the use or
knowledge of a single person, other than the inventor, is sufficient to
constitute public use within the meaning of the statute.47 Third, a use may be
public although it is not observable by the public eye.48
In the case of Smith & Griggs Mfg. Co. v. Sprague,49 Smith & Griggs
employed in their factory a machine that comprised all the elements
contained within two patents. 50 They applied for the patents more than two
34. Kemper, supra note 15, at 62.
35. Id.

36. 104 U.S. 333 (1881).
37. 2-6 CHISUM, supra note 27, § 6.02.
38. Egbert, 104 U.S. at 333.
39. Id. at 335.

40. Id.
41. Id. Egbert later married Barnes. Id.
42. Id.

43. Id.
44. Id. at 336-37.

45. Id.
46. Id. at 336. The court further stated, "one well-defined case of such [public] use is
just as effectual to annul the patent as many." Id.
47. Id. "[Sluch use is public, even though the use and knowledge of the use may be
confined to one person." Id.
48. Id. The Court went on to describe inventions that may constitute parts of a
machine that although unobservable are nevertheless public. Id.
49. 123 U.S. 249 (1887).
50. Id. The application that issued as U.S. Patent No. 228,136 was applied for in 1879.
Id. at 250. The application that issued as U.S. Patent No. 231,199 was applied for in 1878.
Id. The two patents claimed different parts and combinations to construct a single
machine. Id.
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years5 ' after the use.52 The Supreme Court, in holding that the use was
public within the meaning of the statute, set forth experimental use as an
exception "out of the prohibition of the statute" 53 if the use is "properly
characterized as substantially for the purposes of experiment. 54
B. Experimental Use
55
1. City of Elizabeth v. American Nicholson Pavement Co.

City of Elizabeth v. American Nicholson Pavement Co. was one of the
first cases 56 exemplifying the judicially created doctrine of experimental
use. 57 In City of Elizabeth, the inventor of a wooden road laid a seventy-five
foot section of the road down on a private toll road for six years before
applying for a patent. 58 In holding that the use of the road did not constitute
public use,59 the Supreme Court found it important that the purpose of laying
down the road was to test its quality, 60 the road was installed by the inventor
62
at his own expense, 61 the inventor visited the road daily and inspected it,
and the inventor chose the specific site because he wanted to test the road
under different types of traffic.63 In its holding, the Supreme Court found
several issues pertinent to a determination of experimental use: 64 a) although
a device may be tested in private, public testing is not dispositive of public
use; 65 b) for an activity to constitute experimental use, an inventor need not
51. The two-year grace period was in effect during this time. Id.
at 255.
52. Id.at 253.
53. Id.at 255.
54. Id.at 256.
55. 97 U.S. 126 (1877).

56. One commentator has suggested that the experimental use doctrine first arose in
the case of Morris v,Huntington, 17 F. Cas. 818 (C.C.D.N.Y. 1824), with an instruction to
the jury that although the language of the 1793 Patent Act specified that a patent will not
issue if the invention is known or used before the application for patent, if an inventor has
delayed his application because he has been practicing his invention with the intent of
improving it, he should not be prejudiced by the language of the statute. See Rooklidge,
supra note 19, at 9-10 (citing Morris, 17 F. Cas. at 818). Rooklidge went on to suggest
that the Supreme Court adopted the experimental use doctrine as a negation to the public
use bar when it stated that public use, within the meaning of the 1793 Patent Act, could not
be understood as use by the inventor to perfect his invention. See id. at 11-13 (citing
Pennock v. Dialogue 27 U.S. 1 (1829)). Rooklidge further noted that in Shaw v-Cooper
the Supreme Court quoted in full the jury instruction regarding experimental use given by
the court in Morris v. Huntington. See id. at 12-14 (citing Shaw v. Cooper, 32 U.S. 292
(1833)).
57. See Rooklidge, supra note 19, at 16-19 (explaining how courts applied their own
doctrine despite the 1839 Patent Act); see also Kemper, supra note 15, at 39, 63-69, 87-88
(outlining the creation and implementation of the experimental use doctrine).
58. 97 U.S. at 129-33.
59. Id.at 135-36.
60. Id.at 133.
61. Id.
62, Id.
63. Id.at 134.
64. Rooklidge, supra note 19, at 18.
65. See id. (citing City of Elizabeth, 97 U.S. at 134-35).
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alter the invention as a result of the use;6 6 C) if durability is an inherent
quality of the invention, then a long period of experimentation may be
necessary for the inventor to determine if the invention is suitable for its
intended purpose; 67 d) the experimental use does not have to occur on the
inventor's own premises; 6 e) the public may derive a benefit from the
invention that is incidental to the experimental use; 69 f) if the inventor
maintains control over his invention, does not sell it for general use or allow
others to make and use his invention, and uses the invention with the intent
to test its qualities, then the use does not constitute a public use within the
meaning of the statute;70 and g) the inventor must monitor the use for it to be
experimental.71
2.

Public Use Factors

Commentators have identified several factors that courts weigh to
72
determine whether the inventor's use was public or experimental in nature.
Courts will give variable weight to these factors when considering the
"totality of the circumstances" 3 to determine whether a particular use was
experimental or public.
One factor the courts take into consideration is the number and length
of experiments conducted.7 4 These should comport with the nature of the
invention.75 The inventor should also maintain some control over the
experiments,7 6 which should be conducted under some constraints of

66. City ofElizabeth, 97 U.S. at 135.
67. Id.
68. Id.
69. Id.
70. Id.
71. Id.
72. See generally Reforming PatentInfringement, supra note 21 (describing the factors
of the "public use test"). But see Rooklidge, supra note 19, at 48-49 (contending, instead,
that these are factors of experimental use and that the inquiry of whether use is
experimental or public is distinct). It seems well established, however, that courts
generally consider the inquiry of public use versus experimental use as one, with a finding
that experimental use does not fall under public use within the meaning of the statute.
Courts have stated that
it is incorrect to impose on the patent owner, as the trial court in this case did, the
burden of proving that a public use was experimental. These are not two separable
issues. It is incorrect to ask: Was it public use? and then, Was it experimental?
Rather, the court is faced with a single issue: Whether it public use under § 102(b).
TP Labs., Inc. v. Profl Positioners, Inc., 724 F.2d 965, 971 (Fed. Cir. 1984). See also
Reforming Patent Infringement, supra note 21, at 50-51 (arguing that the question of
experimental use is not divorced from the public use inquiry).
73. Sinskey v. Pharmacia Ophthalmics, Inc., 982 F.2d 494, 498 (Fed. Cir. 1992).
"[T]he court must look to the totality of the circumstances to determine whether there has
been a public use within the meaning of section 102(b)." Id.Furthermore, "a decision on
whether there has been a 'public use' can only be made upon consideration of the entire
surrounding circumstances." TP Labs., Inc., 724 F.2d at 972.
74. Kemper, supra note 15, at 66.
75. Id.
76. Id.
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confidentiality.77 Lastly, the experiments should be monitored by the
inventor or by someone on behalf of the inventor.78
3.

The Nature of the Experimental Use

The courts are cognizant of several factors relating specifically to the
invention when determining whether use is experimental or public.
a.

Reduce the Invention to Practice

The use, to be experimental, must be undertaken to reduce the
invention to practice.7 9 Reduction to practice entails perfecting or
completing the invention with respect to its claimed limitations.8° For an
invention to be reduced to practice, it must also be shown that the invention
is suitable for its intended purpose.8 '
b.

Use after Reduction to Practice

Use that occurs after reduction of the invention to practice cannot
constitute experimental use.8 2 Because an inventor engages in experimental
activity for the purpose of perfecting the invention, "experimental use ends
83
upon reduction to practice."
c.

Lack of Reduction to Practice is not Dispositive

Use that occurs before reduction to practice is not always
experimental.8 4 The experimental activity8 must
still be conducted for the
5
purpose of perfecting the claimed invention.
d.

The Claims Define the Invention

It is a
invention. 86
invention.8 7
use, it must
patent. 88

well-known maxim in patent law that the claims define the
The claims of a patent set the metes and bounds of an
For an inventor's use to fall under the rubric of experimental
pertain to the invention as it is defined by the claims of the

77. Id.

78. Id.
79. Rooklidge, supra note 19, at 24.

80. Id.
at 25.
81. Id.
82.
83.
84.
85.

Id.
Id.
Id.
at 26.
Id.

86. Id.
at 35.
87. Id.

88. Id.
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THE FEDERAL CIRCUIT CASES ON PUBLIC USE

In the prior decision of SmithKline Beecham Corp.,89 the Federal
Circuit found the administration of clinical trials to test a novel chemical
91
90
composition to constitute public use within the meaning of the statute.
The main concern was whether the decision comported with other Federal
Circuit decisions regarding public use.92
In SmithKline Beecham Corp., the majority opinion included a
discussion of three major Federal Circuit decisions regarding the
experimental use negation to public use, 93 Manville Sales Corp., v.
ParamountSys., Inc.,94 Seal-Flex, Inc. v. Athletic Track and Court Constr.,9
and EZ Dock, Inc. v. Schafer Sys., Inc.9 6 The majority found these cases to
be consistent with the rationale underlying the decision in SmithKline
Beecham Corp.,97 while the concurrence98 and the Washington Legal
Foundation, writing a brief as Amicus Curiae in support of SmithKline
Beecham Corp.'s petition for rehearing en banc, found these cases to be
irreconcilable with the majority's opinion. 99 This part of the Comment will
address the concern that the prior SmithKline Beecham Corp. decision would
have created an area of uncertainty in patent law.'0 0 First it will examine, in
detail, the prior SmithKline Beecham Corp. decision and its rationale. Then

89. SmithKline Beecham Corp., 365 F.3d 1306.

90. Id. at 1320.
91. 35 U.S.C. § 102.
A person shall be entitled to a patent unless... (b) the invention was patented or
described in a printed publication in this or a foreign country or in public use or on
sale in this country, more than one year prior to the date of the application for
patent in the United States....

Id.
92. Brief for Washington Legal Foundation as Amicus Curiae in Supporting PlaintiffsAppellants' Petition for Rehearing en Banc, SmithKline Beecham Corp. v. Apotex Corp.,
403 F.3d 1331 (Fed. Cir. 2005)(No. 03-1285, 03-1313).
En banc review [of the Federal Circuit's decision in SmithKline Beecham Corp.] is
warranted because the panel decision directly conflicts with numerous decisions of
this Court regarding the scope of the public use bar. As a result of the panel
decision, patent attorneys can no longer competently counsel clients regarding how
to conduct clinical trials to determine whether a drug is effective for its intended
use, without running significant risk that the public use bar will invalidate any
patent later sought for the drug.

Id.
93. SmithKline Beecham Corp., 365 F.3d at 1318.
94. 917 F.2d 544 (Fed. Cir. 1990).
95. 98 F.3d 1318 (Fed. Cir. 1996).
96. 276 F.3d 1347 (Fed. Cir. 2002).
97. 365 F.3d at 1318.
98. Id. at 1324-25 (Gajarsa, J., concurring).
99. Brief for Washington Legal Foundation as Amicus Curiae, supra note 89.
100. SmithKline Beecham Corp., 365 F.3d at 1323 (Gajarsa, J., concurring) (arguing
that the case presented unique circumstances because "something feels wrong about
holding an infringer liable for inevitable, spontaneous infringement," so the majority tried
to twist current case law to achieve the outcome, without addressing the issue head-on).
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it will examine the Federal Circuit decisions in Manville Sales Corp.,101 SealFlex, Inc., °2 and EZ Dock, Inc.' °3 in light of the rationale underlying

SmithKline Beecham Corp. to determine whether the decisions did, in fact,
conflict.
A.
1.

SmithKline Beecham Corp. v. Apotex Corp.

Background

During the late 1970s, Ferrosan, a British company, discovered a new
class of chemical compounds having antidepressant and anti-Parkinson
pharmacological properties. 1°4 This class of compounds came to be known
as paroxetine.10 5 Ferrosan developed a method to crystallize paroxetine,
forming the crystalline hydrochloride salt of paroxetine or paroxetine
hydrochloride (PHC) and licensed it to SmithKline Beecham Corp.° 6 After
obtaining the license, SmithKline Beecham Corp.
started manufacturing
07
paroxetine hydrochloride at its facility in England. 1
SmithKline Beecham Corp. manufactured the anhydrous crystalline
form of paroxetine hydrochloride.' 0 8 Approximately five years later, a
chemist working for SmithKline Beecham Corp. discovered a new and more
stable crystalline form of paroxetine hydrochloride, the hemihydrate.' 0 9
Once this more stable crystalline form of paroxetine hydrochloride emerged
in the laboratories, SmithKline argued that the original form of anhydrous
paroxetine hydrochloride could no longer be made because of a theory they
proposed, and the court adopted, regarding disappearing polymorphs." The
101. See 917 F.2d at 549-51 (holding that the use was not public because, under a
totality of the circumstances, it was clear that experimentation was the primary objective).
102. See 98 F.3d at 1324 (holding than an inventor may engage in commercial activity
and avoid the on-sale bar, provided that inventor is still ascertaining whether the invention
will serve its intended purpose).
103. See 276 F.3d at 1353 (holding that summary judgment on the issue of invalidity is
improper if the patentee provides evidence of experimentation sufficient to negate the
statutory presumption).
104. See SmithKline Beecham Corp., 365 F.3d at 1308 (attributing the invention of a
new class of compounds which contain anti-depressant properties to Ferrosan (citing U.S.
Patent No. 4,007,196 (filed July 23, 1975) (issued Feb. 8, 1977) as relating to all new 3substituted 1-alkyl-4-phenylpiperidines that possessed antidepressant and anti-Parkinson's
pharmacological activity).
105. Id.
106. Id.at 1308-09.
107. Id. at 1309.
108. Id. The anhydrous form of a crystal is a crystal without water bound to the
crystalline lattice. Id.
109. Id. (explaining that the hemihydrate crystal is a crystal bound with water
molecules in a one to two ratio). The hemihydrate crystalline form is more stable than the
anhydrous form because the water molecules are already contained within the crystalline
lattice, so the crystal tends to be less reactive with water. SmithKline Beecham Corp. v.
Apotex Corp., 247 F.Supp.2d 1011, 1017 (N.D. 111. 2003).
110. See SmithKline Beecham Corp., 247 F.Supp.2d at 1019-20 (adopting expert
witness's testimony of "disappearing polymorphs").
Polymorph refers to different
crystalline structures of the same chemical compound. Id. at 1016-17.
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theory of disappearing polymorphs suggests that once a new and more stable
polymorph emerges in a laboratory, the seeds of this crystal will forever be
present and will tend to convert the less stable polymorph into the new
polymorph despite efforts to produce the former. 11 Thus, because of
conversion, efforts to produce the anhydrous form of paroxetine
hydrochloride will
necessarily produce the hemihydrous form of paroxetine
2
hydrochloride. 1
In May 1985, SmithKline Beecham Corp. began conducting doubleblind clinical trials 1 3 in the United States to determine the safety and
efficacy of paroxetine hydrochloride hemihydrate as an antidepressant
agent. 4 On October 23, 1986, SmithKline Beecham Corp. filed a United
States patent application" 15 for antidepressant crystalline paroxetine
hydrochloride that issued on January 26, 1988 as U.S. Patent No. 4,721,723
("the '723 patent")." 6 The patent application was filed more than one year
after commencement of the clinical trial study. 1 7 SmithKline Beecham
Corp. began marketing paroxetine hydrochloride hemihydrate as Paxil© in
1993, after FDA approval." 8
In 1998, Apotex Corp. filed an Abbreviated New Drug Application 1 9
("ANDA") with the Food and Drug Administration ("FDA"), pursuant to 21
U.S.C. § 355(j), 120 seeking approval of a generic paroxetine hydrochloride
anhydrate with bioequivalence to the active ingredient of SmithKline
Beecham Corp.'s Paxil©. Apotex Corp. certified that it intended to market
the drug before expiration of the '723 patent 12 1 because its active ingredient,
22
paroxetine hydrochloride anhydrate, would not infringe the '723 patent.

111. Id.at1019-21.
112. SmithKline Beecham Corp., 365 F.3d at 1312; SmithKline Beecham Corp., 247
F.Supp.2d at 1019-23.

113. In a double-blind clinical study, the participating individuals and the study staff are
not apprised of "which participants are receiving the experimental drug and which are
receiving a placebo."
ClinicalTrial.gov, Glossary of Clinical Trials Terms,
http://www.clinicaltrials.gov/ct/info/glossary (last visited Nov. 1, 2004).
114. SmithKline Beecham Corp., 365 F.3d at 1309.

115. U.S. Patent Application No. 922,530 (filed Oct. 23, 1986).
116. U.S. Patent No. 4,721,723 (filed Oct. 23, 1986) (issued Jan. 26, 1988).
117. See 35 U.S.C. § 102 (codifying that "a person shall be entitled to a patent
unless... (b) the invention was.., in public use or on sale in this country, more than one
year prior to the date of the application for patent in the United States").
118. SmithKline Beecham Corp., 365 F.3d at 1309.
119. Id.
120. See 21 U.S.C. § 3550) (2000) (providing for new (generic) drug approval using an
abbreviated application). "An application for a new drug shall contain - information to
show that the rate of administration, the dosage form, and the strength of the new drug are
the same as those of the listed drug referred to in the clause." 21 U.S.C. §355(j)(2)(A)(iii).
The applicant must "show that the new drug is bioequivalent to the listed drug." 21 U.S.C.
§ 3556)(2)(iv).
121. SmithKline Beecham Corp., 365 F.3d at 1309.
122. The '723 patent recites six claims. Claim 1 recites only the structure of the
chemical compound, "[c]rystalline paroxetine hydrochloride hemihydrate." Id.Claims 26 are more specific, limiting the claims to substantially pure forms of the crystal or to
chemical compositions of the crystal that have an antidepressant effect. Id. Claim 1 is the
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Pursuant to 35 U.S.C. § 271(e)(2), 2 3 SmithKline Beecham Corp. initiated an
infringement action against Apotex Corp., 24 alleging that Apotex Corp.
indicated in the ANDA that it intended to market a generic paroxetine
hydrochloride anhydrate that would necessarily convert to paroxetine
hydrochloride
hemihydrate 25 and would, thus, infringe Claim I of the '723
26
1

patent.

broadest claim, giving SmithKline Beecham Corp. the right to exclude others from
making, using, or selling paroxetine hydrochloride hemihydrate, even in the most
minuscule amount (a single crystal) and regardless of whether the infringing chemical
compound has any antidepressant effect. Id.
123. 35 U.S.C. § 271(e)(2)(A) (2000) "It shall be an act of infringement to submit...
an application under section 5050) of the Federal Food, Drug, and Cosmetic Act or
described in section 505(b)(2) of such Act for a drug claimed in a patent or the use of
which is claimed in a patent .... " Id.
124. SmithKline Beecham Corp., 365 F.3d at 1309.
125. Id.
126. Id. The right of Apotex Corp. to file an abbreviated drug application without
conducting its own tests for safety and efficacy and SmithKline Beecham Corp. to sue
Apotex Corp. for infringement have a common source, the Drug Price Competition and
Patent Term Restoration Act ("Hatch-Waxman Amendments") that amended the Federal
Food, Drug, and Cosmetics Act. Laura J. Robinson, Analysis of Recent Proposals to
Reconfigure Hatch- Waxman, 11 J. INTELL. PROP. L. 47, 52 (2003). Until Hatch-Waxman,
generic drug manufacturers had to perform the same safety and efficacy studies as brand
name manufacturers to get approval. Id. The generic manufacturer could not demonstrate
the safety and efficacy of its "bio-equivalent" drug by relying on the animal and human
studies conducted by the brand name manufacturer. Id. If the generic manufacturer
attempted to conduct safety and efficacy tests before the expiration of the patent, however,
it would necessarily infringe the patent by making and using a patented product for
commercial purposes, as opposed to mere scientific inquiries, which would have been
allowable. Roche Prods., Inc., v. Bolar Pharm. Co. Inc., 733 F.2d 858, 863 (Fed. Cir.
1984). The Roche Prods., Inc. decision effectively extended the period of exclusivity for
the patent owner beyond the term of the patent to include the time generic manufacturers
would need from expiration of the patent until completion of their clinical studies.
SmithKline Beecham Corp., 247 F. Supp. 2d at 1018. In the efforts to promote the
availability of affordable generic alternatives to pharmaceutical drugs, Congress responded
with the Hatch-Waxman Amendments in 1984. Sarah E. Eurek, Comment, HatchWaxman Reform and Accelerated Market Entry of Generic Drugs: Is Faster Necessarily
Better?, 2003 DUKE L. & TECH. REv. 18, 19 (2003). The Hatch-Waxman Amendments
allowed generic manufacturers to file abbreviated new drug applications, whereby the
generic manufacturer needs only to demonstrate to the FDA that its drug is the
bioequivalent of the brand name drug to satisfy the safety and efficacy requirements.
Robinson, supra, at 52. The Hatch-Waxman Amendments also created an exception to the
rule against infringement for generic drug manufacturers seeking FDA approval, giving
the generic manufacturer the right to make and use the generic version of the drug before
patent expiration. Id. The Hatch-Waxman Amendments did not leave the brand name
manufacturers without recourse. Id. at 53-55. If a generic drug manufacturer wants to
enter the market with its generic version of a patented drug before the patent term expires,
it must file a paragraph IV certification and provide notice to the brand name
manufacturer. Id. at 55-56. Paragraph IV certification requires the generic manufacturer
to indicate that it believes either it is not infringing the brand name manufacturer's patent
or the brand name manufacturer's patent is invalid. Id. Under Hatch-Waxman, a
paragraph IV certification, in turn, gives the brand name manufacturer the opportunity to
bring action against the generic drug manufacturer for infringement. Id. at 56.
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'723 Patent is Infringed

The majority began its analysis by construing the scope of Claim 1 of
the '723 patent. 2 7 Claim 1 recites "crystalline paroxetine hydrochloride
hemihydrate.' 2 8 The majority found this claim language to be unambiguous
and to clearly claim a chemical structure. 129 The majority, adopting the
disappearing polymorph theory, also found that because the more stable
hemihydrate of paroxetine had emerged, any attempt by Apotex Corp. to
manufacture the unclaimed paroxetine anhydrate would necessarily fail
because the anhydrate would convert into the hemihydrate form.130 Thus,
any attempt by Apotex Corp. to manufacture the non-infringing anhydrous
product would lead to infringement of the '723 patent because some
miniscule amount of paroxetine hemihydrate would always form. Apotex
Corp., therefore, infringed the '723 patent by making and using paroxetine
hydrochloride hemihydrate (albeit, in miniscule amounts). 131
3.

'723 Patent is Invalidfor Public Use

The majority, however, did not stop after finding infringement of the
'723 patent. It went on to discuss the crucial aspect of the case - did
SmithKline Beecham Corp.'s clinical trials constitute public use? 32 The
majority stated that 35 U.S.C. § 102(b) creates a bar to obtaining a patent if
the invention was ready for patenting and was used by one other than the
inventor who is not under the constraints of confidentiality more than one
year before filing a patent application. 133
The majority found that SmithKline Beecham Corp.'s clinical trials did
not constitute experimental use because the doctrine applied only to features
of the claimed invention. 3 4 The majority focused on the language and scope
of the claim. 135 Claim 1 of the '723 patent claimed a naked chemical
structure, with no reference to the safety of the chemical for human use or its
efficacy as an antidepressant. 136 The majority espoused the rule that
37
experimental testing cannot occur once an invention is reduced to practice. 1
For infringement, SmithKline Beecham Corp. argued that the scope of Claim

127. SmithKline Beecham Corp., 365 F.3d at 1313.
128. Id. at 1315.
129. Id.
130. Id. at 1312-13.
131. Id. at 1315.
132. Id. at 1316.
133. Id. at 1316-17. The majority posited this two-part test for the public use bar upon
the incorrect assumption that the two-part test for the on sale bar established in Pfaff v.
Wells Elecs., Inc., 525 U.S. 55 (1998), also applies to public use. See infra Part IV for a
discussion of the majority's characterization of the two-part test for public use.
134. SmithKline Beecham Corp., 365 F.3d at 1317-18. See also, LaBounty Mfg. v.
United States ITC, 958 F.2d 1066, 1074 (Fed. Cir. 1992) (stating that the law is well
settled that an experimental sale can only apply to claimed features of the invention).
135. SmithKline Beecham Corp., 365 F.3d at 1318.
136. Id. "The antidepressant properties of the compound are simply not claimed
features." Id.
137. Id. at 1318-19.
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I of the '723 patent did not imply any intended commercial significance or
pharmaceutical benefit; it argued, therefore, that Apotex Corp. would
infringe even if it makes trace amounts of the patented chemical, even if the
amount of the chemical is so miniscule that it confers no antidepressant
effect.'
The majority turned SmithKline Beecham Corp.'s own argument
around to conclude that if efficacy is not an element of the claimed invention
when evaluating infringement, then it is also not available when evaluating
whether experiments were conducted to test features of the claimed
invention. 39
The rationale of the majority is best summed up by the statement: A use
can only be experimental
if it is limited to explicit or inherent features of the
1 40
invention.
claimed
The question now is whether this rationale applies to the Federal
Circuit's public use cases.

B. Manville Sales Corp. v. Paramount Sys., Inc.
1.

The Claimed Invention

The Manville Sales Corp. owned U.S. Patent No. 3,847,333 ("the '333
patent") for an apparatus designed to maintain a ring-like luminaire support
centered around a light pole. 14 The claims specified that the apparatus must
maintain the ring-like object around the external surface of a post or a
predetermined location.142
2.

The Alleged Public Use

Manville constructed the assembly and then had it placed on a light
pole in a remote Wyoming rest area, which was not yet open to the public, to
determine whether the light assembly could withstand the outdoor
environment. 143
3.

Was the Use Experimental?

The court found that durability was inherent to the purpose of the
invention. 44 This, however, can be reconciled with the decision in
SmithKline Beecham Corp. because in order to maintain the ring-like

138. Id. at 1320.
139. Id.
140. Id. at 1319-20.

141. U.S. Patent No. 3,847,333 (issued Nov. 12, 1974). The language of claims 1 and 9
call for "an apparatus for maintaining a ring-like object support in a predetermined
location around the external surface of a post." Id. Claims 10, 15, and 16 call for "an
apparatus adapted for centering a ring-like object support about the axis of a longitudinal
member." Id. Claim 11 calls for a "luminaire assembly comprising... a ring-like support
member concentrically disposed around said post." Id.
142. Id.
143. Manville Sales Corp. v. Paramount Sys., Inc., 917 F.2d 544, 550 (Fed. Cir. 1990).
144. Id. at551.
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structure around a pole, the apparatus must be durable; therefore, durability
is an inherent feature of the claimed invention.
C. Seal-Flex, Inc. v. Athletic Track and Court Constr.
1.

The Claimed Invention

Seal-Flex owned U.S. Patent No. 4,539,622, which claimed an "activity
mat over a foundation.' 45
2.

The Alleged Public Use

Seal-Flex sold its athletic track to, and installed it in, a local high
school.1 46 Seal-Flex continued to monitor the track47 after installation and
student use, and made repairs and design alterations. 1
3.

Was the Use Experimental?

The court concluded that the use was experimental and needed to show
that the invention worked for its intended purpose. 48 Applying the
SmithKline Beecham Corp. rationale, the experiments tested the inherent
features of the invention because an activity mat implies, as a claimed
feature, durability under use.
D. EZ Dock, Inc. v. Schafer Sys., Inc
1.

The Claimed Invention

EZ Dock owned U.S. Patent No. 5,281,055, which claimed a "floating
49

dock.'
2.

1

The Alleged Public Use

EZ Dock sold the invention to a person who used it on rough water and
monitored it after installation, making repairs to the dock and changes to the
design. "So

3.

Was the Use Experimental?

The court held that the use was experimental because "floating docks,
by their nature, must endure all kinds of water conditions."' 151 The court
therefore concluded that the experiment tested an inherent feature of the
claimed invention.

145. U.S. Patent No. 4,529,622 (issued July 16, 1985).
146. Seal-Flex, Inc. v. Athletic Track and Court Constr., 98 F.3d 1318, 1320 (Fed. Cir.
1996).
147. Id.
148. Id. at 1323.
149. U.S. Patent No. 5,281,055 (filed July 17, 1992) (issued Jan. 25, 1994).
150. EZ Dock, Inc. v. Schafer Sys., Inc., 276 F.3d 1347, 1349 (Fed. Cir. 2002).
151. Id. at 1353.
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IV. PROMOTING CERTAINTY IN PATENT LAW

The Federal Circuit sitting in a three-judge panel wrote the prior
SmithKline Beecham Corp. decision. 152 On June 4, 2004, SmithKline
Beecham Corp. petitioned for en bane review following the panel's decision
on public use. 153 The Washington Legal Foundation filed a brief as Amicus
Curiae in support of SmithKline Beecham Corp.'s petition for rehearing en
bane, arguing that en bane review was warranted because SmithKline
Beecham Corp. conflicted with prior decisions with respect to public use and
created uncertainty with its characterization of the reach of the experimental
use doctrine. 54 This part of the Comment will address the Washington
Legal Foundation's concerns. The Comment will propose that the majority's
characterization of the experimental use doctrine was technically correct and
in accord with previous case law, and will then discuss the majority's twopart test for public use.
A.

Delineatingthe Boundariesof Experimental Use

Predictability, certainty, and consistency are the most important aspects
of patent law, where significant property interests are at stake.155 Attorneys
often counsel clients on issues regarding whether certain actions by the
inventor may constitute public use to bar the issuance of a patent. 56 Courts
may view actions that intuitively seem necessary to develop an invention as
public use. The Federal Circuit's lack of discussion in vacating the prior
SmithKline Beecham Corp. decision has left open whether clinical trials may,
in the future, be considered public use.
Several commentators have suggested that despite creation of the
Federal Circuit to promote consistency in patent law, there is, in fact, little
consistency in the decisions regarding public use. 157 Moreover, the
Washington Legal Foundation expressed great concern that the prior
SmithKline Beecham Corp. decision dealt another blow to the consistency of
Federal Circuit decisions by holding that "a clinical study ... [that] fits most
everyone's understanding... of an 'experimental use' of a product"
constitutes public use. 158 This assertion lies on faulty reasoning. The
experimental use doctrine applies to an invention, not to a product. 59
152. SmithKline Beecham Corp., 365 F.3d at 1307 (Fed. Cir. 2004).
153. SmithKline Beecham Corp. v. Apotex Corp., No. 99-CV-4304, 2004 U.S. Dist.
LEXIS 13907, at *12-13 (E.D. Pa. July 16, 2004).
154. Brief for Washington Legal Foundation, supra note 89.
155. Katherine E. White, Note, A General Rule of Law is Needed to Define Public Use
in Patent Cases, 88 KY. L.J. 423, 423 (2000).
156. Brief for Washington Legal Foundation, supra note 89.
157. See generally White, supra note 152 (finding a lack of consistency in public use
and on-sale bar cases); Margaret L. Begalle, Note, Eliminating the Totality of the
Circumstances Test for the Public Use Bar Under Section 102 (B) of the Patent Act, 77
CHI.-KENT. L. REV. 1359 (2002) (suggesting that alternatives to the totality of the

circumstances test may provide more consistency in patent law decisions).
158. Brief for Washington Legal Foundation, supra note 89.
159. See infra note 157 and accompanying text (discussing experimental use as it
applies to inventors).
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Additionally, the prior SmithKline Beecham Corp. decision outlined the
boundaries of the experimental use doctrine by positing a clear definition of
experimental use that would have enabled a more accurate prediction of what
activities would qualify under the negation.
1.

Experimental Use Must Pertainto the Claimed Invention

If there is one maxim in patent law, it is that claims define the
invention. 60 Determining the scope of the claim depends upon the claim
language.' 6' Another well-settled principle in patent law is that experimental
use must pertain to the claimed invention. 162 The majority in the prior
SmithKline Beecham Corp. decision merely restated this principle and
appropriately refined the definition of experimental
use to cover both express
163
and implied features of a claimed invention.
2. SmithKline Beecham Corp. was Consistent with the Accepted Definition
of Experimental Use
In all of the Federal Circuit cases discussed in Part III, the claim
language implied features of the invention that must be present for the
invention to perform as claimed. 64 In SmithKline Beecham Corp.'s '723
patent, by contrast, Claim 1 recites nothing more than a chemical structure
that implies no commercial or pharmaceutical value. 165 The remaining
160. "It is a bedrock principle of patent law that the claims of a patent define the
invention..I.." Innova/Pure Water, Inc. v. Safari Water Filtration Sys., 381 F.3d 1111,
1115-16 (Fed. Cir. 2004) (citing, inter alia, Altoona Publix Theaters, Inc. v. Am. TriErgon Corp., 294 U.S. 477, 487 (1935) ("Under the statute it is the claims of the patent

which define the invention.")); Smith v. Snow, 294 U.S. 1, 11 (1935) ("The claims of a
patent, not its specifications, measure the invention."); Cont'l Paper Bag Co. v. E. Paper
Bag Co., 210 U.S. 405, 419 (1908) ("In making his claim the inventor is at liberty to
choose his own form of expression, and while the courts may construe the same in view of
the specifications and the state of the art, they may not add to or detract from the
claim.")(quoting Cimiotti Unhairing Co. v. Am. Fur Ref Co., 198 U.S. 399, 410 (1905));
White v. Dunbar, 119 U.S. 47, 52 (1886) ("The claim is a statutory requirement,
prescribed for the very purpose of making the patentee define precisely what his invention
is; and it is unjust to the public.., to construe it in a manner different from the plain
import of its terms."); Merrill v. Yeomans, 94 U.S. 568, 570 (1876) ("[The statutorily
required] distinct and formal claim is, therefore, of primary importance, in the effort to
ascertain precisely what it is that is patented to the appellant in this case."); SRI Int'l v.
Matsushita Corp. of Am., 775 F.2d 1107, 1121 (Fed. Cir. 1985) (en banc) ("It is the claims
that measure the invention.").
161. Innova/Pure Water, Inc., 381 F.3dat 1116.
162. In re Brigance, 792 F.2d 1103, 1109 (Fed. Cir. 1986) (stressing that "the
experimental use exception does not apply to experiments performed with respect to nonclaimed features of an invention"); W. Marine Elecs., Inc. v. Furuno Elec. Co., 764 F.2d
840, 847 (Fed. Cir. 1985) ("[T]esting or experimentation performed with respect to nonclaimed features of the device does not show that the invention was the subject of
experimentation."); In re Theis, 610 F.2d 786, 793 (C.C.P.A. 1979) ("It is settled law that
the experimental sale exception does not apply to experiments performed with respect to
non-claimed features of an invention.").
163. SmithKlineBeecham Corp., 365 F.3d at 1319-20.
164. See supra notes 142, 146, 150 and accompanying text.
165. '723 patent. "We claim ... crystalline paroxetine hydrochloride hemihydrate." Id.
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claims are more specific, and limit the scope of the invention by adding
commercial ("paroxetine hydrochloride in substantially pure form") and
pharmaceutical
("an antidepressant
pharmaceutical
composition")
significance.1 66 SmithKline Beecham Corp. conceded this point by arguing
that the claim had no implications beyond the express language of the
claim. 167 In fact, SmithKline Beecham Corp. proposed this claim
construction to allow the court to broadly construe the scope of Claim I of
the '723 patent, enabling it to capture Apotex's attempt to manufacture a
non-infringing product. 168 This broad claim construction would have
eviscerated any careful attempt to make the unpatented paroxetine
hydrochloride anhydrate without infringing the patent covering the
hemihydrate. This would have effectively
extended SmithKline Beecham
69
Corp.'s patent to unpatented material. 1
3. SmithKline Beecham Corp. Would not have Disturbeda Patentee's
Efforts to Testfor Utility
The majority's prior definition of experimental use would not have
interfered with a patentee's ability to test for utility of an invention. A
composition of matter claim, such as Claim I of the '723 patent, must have
sufficient minimum utility to obtain a patent. 70 How can a patentee
determine sufficient minimum utility of a novel pharmacological compound
without subjecting it to human clinical trials? In Fujikawa v. Wattanasin, the
Federal Circuit held that any pharmacological activity, including in vitro

testing, could sufficiently establish minimum utility. 7 ' Therefore, regardless
of whether a patentee seeks to market a chemical composition for a specific
166. Id.
167. SmithKlineBeecham Corp., 365 F.3d at 1319.
168. '723 patent claimed paroxetine hydrochloride hemihydrate. Apotex, however, was
attempting to manufacture and market the anhydrate version of the drug. SmithKline
Beecham Corp., 365 F.3d at 1309.
169. And, in this case, unpatentable material. Recall that Ferrosan obtained U.S. Patent
No. 4,007,196 (issued Feb. 8, 1977) over paroxetine hydrochloride in 1977. '196 Patent.
Ferrosan's patent covered the anhydrous form. Id. Therefore, under 35 U.S.C. § 102 (b),
the anhydrous form of paroxetine hydrochloride hemihydrate was unpatentable in the
United States. 35 U.S.C. § 102.
During the prior decision, the panel overlooked the alternative ground upon which to
decide the case. The court paid little attention to the scope of Ferrosan's '196 patent
beyond noting that it covered the anhydrous form of paroxetine hydrochloride. Had the
court focused on the scope of the '196 patent and the fact that there is no evidence to
suggest that the chemist who "discovered" the new and more stable crystalline form of
paroxetine hydrocholoride was doing anything other than practicing the prior art (the '196
patent), the court may have recognized inherent anticipation as an alternative ground for
invalidating SmithKline Beecham Corp.'s '723 patent. The Federal Circuit stated that a
prior art reference may anticipate without disclosing a feature of the claimed invention if
that missing characteristic is necessarily present, or inherent. Schering Corp. v. Geneva
Pharm., Inc., 339 F.3d 1373, 1377 (Fed. Cir. 2003). Applying the previous case law, the
same panel subsequently invalidated claim 1 of the '723 patent on remand on the ground
of inherent anticipation. SmithKline Beecham Corp., 403 F.3d at 1345.
170. 1-4 CHISUM, supra note 27, § 4.02.
171. Fujikawa v. Wattanasin, 93 F.3d 1559, 1564-66 (Fed. Cir. 1996).
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purpose, such as a pharmaceutical agent, the patentee can establish sufficient
minimum utility of the chemical composition before subjecting it to clinical
tests. In this situation, emphasis must be placed again on the scope of the
claim. A chemical composition of matter claim pertains only to a chemical
structure. 172 If the claim is narrower than a mere chemical composition, and
recites specific limitations upon the chemical composition, such as stating
that it is an effective antidepressant agent, then minimum utility must include
evidence that the invention functions as claimed, namely, as an
antidepressant. 173 In that situation, clinical trials would be appropriate, if not
necessary, modes of experimentation to test the claimed invention.
Therefore, an attorney counseling a client on whether the inventor's actions
constitute experimental use need not look further than the inventor's patent.
B.

SmithKline Beecham Corp. Attempted to Create a New Two-Part Test
for Public Use

The majority in the prior SmithKline Beecham Corp. decision
erroneously applied a two-part test for public use. The majority correctly
stated that in Pfaffv. Wells Electronics,Inc. 174 the Supreme Court eliminated
the totality of the circumstances test for the on sale bar, adopting a two-part
test. 75 Pfaff however, does not apply to public use cases. 76 The Federal
Circuit established the totality of the circumstances test for public use in TP
Lab., Inc., v. ProfessionalPositioners, Inc. 177 The three-judge panel that
decided SmithKline Beecham Corp. was not competent to overrule TP Lab.,
Inc. because Federal Circuit panel decisions are binding on all subsequent
78
panels, unless overruled en banc.

1-4 CHISuM, supra note 27, § 4.02.
173. See generally SmithKline Beecham Corp., 365 F.3d 1306 (Fed. Cir. 2004).
174. 525 U.S. 55 (1998).
175. Id. at 66-67. The Court stated:
We conclude, therefore, that the on-sale bar applies when two conditions are
satisfied before the critical date. First, the product must be the subject of a
commercial offer for sale... Second, the invention must be ready for patenting.
That condition may be satisfied in at least two ways: by proof of reduction to
practice before the critical date; or by proof that prior to the critical date the
inventor had prepared drawings or other descriptions of the invention that were
sufficiently specific to enable a person skilled in the art to practice the invention.
Id. at 67.
176. See White, supra note 152, at 424 (discussing the need to eliminate the totality of
the circumstances test for public use and to create a two-part test fashioned after Pfaff that
replaces the first prong of the Pfaff test with the condition that the invention must be
dedicated to the public or there must be detrimental public reliance that the invention is in
the public domain); Begalle, supra note 154.
177. 724 F.2d 965, 972 (Fed. Cir. 1984).
178. EI-Shifa Pharn. Indus. Co. v. United States 378 F.3d 1346, 1352 (Fed. Cir. 2004).
"[T]o overrule a precedent, the court must rule en banc." Id. "This court has adopted the
rule that prior decisions of a panel of the court are binding precedent on subsequent panels
unless and until overturned en banc." Newell Co., Inc. v. Kenney Mfg. Co., 864 F.2d 757,
765 (Fed. Cir. 1988).
172.
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Public Use or Experimental Use
CONCLUSION

In the aftermath of SmithKline Beecham Corp., questions remain as to
whether clinical trials may constitute public use. With the Federal Circuit's
decision to vacate the prior SmithKline Beecham Corp. decision regarding
experimental use without discussion, it has left open the question. The
reasoning behind the panel's prior decision would have promoted certainty in
patent law by reinforcing the limitation of experimental use to explicit or
inherent features of the claimed invention. Application of that reasoning to
clinical trials, however, seems unpalatable in light of the enormous amounts
of time, effort, and money that pharmaceutical companies pour into research
and development. The reasoning seems less controversial, however, when
applied to other patented inventions, such as a dock, activity mat, or light
assembly to be mounted on a light pole.
Moreover, clinical trials would still constitute experimental use if the
inventor is diligent in testing the claimed features of the invention. This
outcome breathes equity into patent law by allowing an inventor to predict
whether an experimental activity is permissible by simply looking to the
language of the claim.

